PCRI Announces FDA-Approved Xofigo for Men with CRPC, and Early Registration for the 2013 Prostate Cancer Conference

Share Article

Recently approved Xofigo, formally known as Alpharadin, is now available for men with CRPC, and until June 30, 2013 Prostate Cancer Conference attendees can register for a discounted rate.

News Image

The Prostate Cancer Research Institute announced recent FDA approval of Xofigo (radium 223), and discounted early registration for the 2013 Prostate Cancer Conference until June 30.

The recent FDA approval of Xofigo, formally known as Alpharadin, is a new drug for men with Castrate Resistant Prostate Cancer (CRPC) who have bone metastasis, bone pain, and no known visceral metastases.

Xofigo is an injectable radiation treatment to treat prostate cancer that is administered slowly over 60 seconds by a Radiation Oncologist or a Nuclear Medicine Physician, about every 4 weeks for up to 6 treatments. Immediately following the FDA approval of a drug, it can take some time to get the medicine to every doctor treating CRPC patients, as well as provide training necessary and other aspects that can only be started after the drug is approved. If patients need to travel for treatment, travel support programs can be found at http://www.xofigo-us.com or by calling 1-855-696-3446.

While Xofigo was not studied as a primary treatment for CRPC, it was found to have two cancer responses as a supplemental treatment: improvement in bone pain, and survival benefit. Side effects were found to be minimal and treatable, including low lymphocytes (32% more than placebo, low white blood cells (28% more than placebo) and low platelets (12% more than placebo).

PCRI also announced that 2013 Prostate Cancer Conference attendees can register for the conference before June 30 for only $60. After that, registration fees are $120 through September 5. Registration fees include access to the conference and to support group meetings. The 2013 conference will be held at the Marriott Los Angeles Airport Hotel from September 6-8.

Attendees are also encouraged to arrange travel plans that allow for early arrival on Friday, September 6, for extensive programs available Friday afternoon. On Saturday, September 7, attendees will be able to attend a live biopsy where Dr. Duke Bahn, Medical Director of the Prostate Institute of America at Community Memorial Hospital in Ventura, California, will provide specific and personal advice with an onstage presentation.

For more information regarding available sponsorship opportunities for the conference, contact Cathy Williams at 310-743-2116.

About PCRI
The Prostate Cancer Research Institute is a charitable non-profit organization dedicated to supporting research to improve the quality of men’s lives, and providing information that both educates and empowers patients, families and the medical community. Founded in 1996 by internationally recognized prostate cancer oncologists Mark C. Scholz, MD and Stephen B. Strum, MD, with support from Daniel Freeman Hospital Foundation, PCRI provides programs and services to support their mission and goals. Such programs and resources include a help line, an informative and up-to-date website, newsletters, annual conferences, advocacy, and research.

For more information, visit http://www.prostate-cancer.org.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Cathy Williams
Follow us on
Visit website